A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.
Latest Information Update: 23 May 2025
At a glance
- Drugs Skin disorder therapies (Primary)
- Indications Skin aging
- Focus Adverse reactions; First in man
- Sponsors SIPO Biotechnology
Most Recent Events
- 15 May 2025 Planned End Date changed from 15 Dec 2025 to 15 Dec 2027.
- 15 May 2025 Planned primary completion date changed from 15 Mar 2025 to 12 Nov 2027.
- 15 May 2025 Planned initiation date changed from 1 Jan 2025 to 12 Nov 2025.